Improving clinical trial design for Duchenne muscular dystrophy

Area of Science:

• Neurology
• Genetics
• Clinical Trial Design

Background:

• Duchenne muscular dystrophy (DMD) therapies like exon skipping aim to restore dystrophin.
• Previous trials, such as with drisapersen, have not met primary outcome measures like the six-minute walk test.

Purpose of the Study:

• To review key considerations for designing effective clinical trials for novel Duchenne muscular dystrophy therapies.
• To propose improvements in patient selection, trial endpoints, and approval pathways.

Main Methods:

• Review of current Duchenne muscular dystrophy (DMD) therapeutic strategies and clinical trial methodologies.
• Analysis of factors influencing trial outcomes, including patient age, corticosteroid use, and expected treatment effects.

Main Results:

• Younger patients with more preserved muscle are better candidates for demonstrating treatment efficacy.
• Corticosteroid use in both treatment and placebo groups can confound results.
• The expectation for these therapies is disease stabilization, not functional improvement.

Conclusions:

• Clinical endpoints should focus on prolonging functional abilities (standing, walking) rather than increasing strength.
• Surrogate biochemical outcomes like de novo dystrophin production are crucial for accelerated approval.
• Trial designs must adapt to DMD's characteristics to accurately assess therapeutic benefits.